Entecavir anhydrous | CAS#142217-69-4 | Reverse Transcriptase Inhibitor

MedKoo Cat#: 317776 | Name: Entecavir anhydrous

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Entecavir is a reverse transcriptase inhibitor. It is an oral antiviral drug used in the treatment of hepatitis B virus (HBV) infection. It prevents the hepatitis B virus from multiplying and reduces the amount of virus in the body. More specifically, it is a deoxyguanosine analogue, that inhibits reverse transcription, DNA replication and transcription in the viral replication process. The chemical classification of entecavir anhydrous is Nucleoside Analog.

Chemical Structure

Entecavir anhydrous

CAS#142217-69-4 (free)

Theoretical Analysis

MedKoo Cat#: 317776

Name: Entecavir anhydrous

CAS#: 142217-69-4 (free)

Chemical Formula: C12H15N5O3

Exact Mass: 277.1175

Molecular Weight: 277.28

Elemental Analysis: C, 51.98; H, 5.45; N, 25.26; O, 17.31

Price and Availability

Size	Price	Availability
50mg	USD 250.00	2 weeks
100mg	USD 400.00	2 weeks
250mg	USD 750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

142217-69-4 (free) 209216-23-9 (hydrate) 911138-73-3 (maleate) 188399-46-4 (enantiomer)

Synonym

Entecavir; Baraclude; BMS-200475; BMS-200475; BMS-200475; FT-0083013; FT0083013; FT0083013; D07896; SQ 34676; SQ-34676; SQ34676;

IUPAC/Chemical Name

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-3H-purin-6-one

InChi Key

QDGZDCVAUDNJFG-FXQIFTODSA-N

InChi Code

InChI=1S/C12H15N5O3/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20)/t6-,7-,8-/m0/s1

SMILES Code

O=C1N=C(N)NC2=C1N=CN2[C@@H]3C([C@H](CO)[C@@H](O)C3)=C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot# S9G01M28

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Entecavir (SQ 34676; BMS 200475) is a potent and selective inhibitor of HBV, with an EC50 of 3.75 nM in HepG2 cell.

In vitro activity:

Based on the above results, this study further evaluated whether entecavir could act as a P2X7R antagonist to influence platelet aggregation. As shown in Fig. 2A, a 2500× magnification of images presented that platelets formed large, stable aggregates and the parapodium stretched out in thrombin-activated platelet, while entecavir or AZD9056 treatment remarkably prevented aggregate formation (Fig. 2A). To further confirm this result, the real-time platelet aggregation was tested. Platelet aggregation in response to thrombin stimulation was inhibited in a concentration dependent manner in the presence of entecavir (Fig. 2B and C). Likewise, AZD9056 resulted in a reduction to 34.9% ± 5.3% in platelet aggregation (Fig. 2B and C). Reference: J Pharmacol Sci. 2020 Sep;144(1):43-51. https://pubmed.ncbi.nlm.nih.gov/32653340/

In vivo activity:

The comparison of gut microbiota composition of rAAV8-HBV-infected mice and ETV (Entecavir)-treated mice with healthy controls was carried out using 16S rDNA sequencing analysis of caecal content samples. The intestinal microbiota alpha diversity of rAAV8-HBV-infected mice decreased, and significantly restored after 4 weeks of ETV therapy. Reference: Int J Antimicrob Agents. 2020 Jul;56(1):106000. https://pubmed.ncbi.nlm.nih.gov/32360229/

	Solvent	mg/mL	mM
Solubility
	DMSO	42.2	152.34

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 277.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Ming Y, Xin G, Ji B, Ji C, Wei Z, Zhang B, Zhang J, Yu K, Zhang X, Li S, Li Y, Xing Z, Niu H, Huang W. Entecavir as a P2X7R antagonist ameliorates platelet activation and thrombus formation. J Pharmacol Sci. 2020 Sep;144(1):43-51. doi: 10.1016/j.jphs.2020.07.002. Epub 2020 Jul 3. PMID: 32653340. 2. Li X, Wu S, Du Y, Yang L, Li Y, Hong B. Entecavir therapy reverses gut microbiota dysbiosis induced by hepatitis B virus infection in a mouse model. Int J Antimicrob Agents. 2020 Jul;56(1):106000. doi: 10.1016/j.ijantimicag.2020.106000. Epub 2020 Apr 29. PMID: 32360229.

In vitro protocol:

In vivo protocol:

1. Li X, Wu S, Du Y, Yang L, Li Y, Hong B. Entecavir therapy reverses gut microbiota dysbiosis induced by hepatitis B virus infection in a mouse model. Int J Antimicrob Agents. 2020 Jul;56(1):106000. doi: 10.1016/j.ijantimicag.2020.106000. Epub 2020 Apr 29. PMID: 32360229.

1: Kuo MH, Tseng CW, Lu MC, Tung CH, Tseng KC, Huang KY, Lee CH, Lai NS. Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment. Dig Dis Sci. 2021 Jan 2. doi: 10.1007/s10620-020-06725-1. Epub ahead of print. PMID: 33387124. 2: Araujo NM, Teles SA, Spitz N. Comprehensive Analysis of Clinically Significant Hepatitis B Virus Mutations in Relation to Genotype, Subgenotype and Geographic Region. Front Microbiol. 2020 Dec 14;11:616023. doi: 10.3389/fmicb.2020.616023. PMID: 33381105; PMCID: PMC7767914. 3: Manolakopoulos S, Kranidioti H, Kourikou A, Deutsch MM, Triantos C, Tsolias C, Manesis EK, Mathou N, Alexopoulou A, Hadziyannis E, Papatheodoridis G. Long- term clinical outcome of HBeAg-negative chronic hepatitis B patients who discontinued nucleos(t)ide analogues. Liver Int. 2021 Jan;41(1):48-57. doi: 10.1111/liv.14654. PMID: 33373114. 4: Ahn YE, Suh SJ, Kim TH, Jung YK, Yim HJ. Maintaining Antiviral Efficacy after Switching to Generic Entecavir 1 mg for Antiviral-resistant Chronic Hepatitis B. Korean J Gastroenterol. 2020 Dec 30. doi: 10.4166/kjg.2020.0144. Epub ahead of print. PMID: 33372170. 5: Broquetas T, Garcia-Retortillo M, Micó M, Canillas L, Puigvehí M, Cañete N, Coll S, Viu A, Hernandez JJ, Bessa X, Carrión JA. Hepatitis B surface antigen and hepatitis B core-related antigen kinetics after adding pegylated-interferon to nucleos(t)ids analogues in hepatitis B e antigen-negative patients. World J Hepatol. 2020 Nov 27;12(11):1076-1088. doi: 10.4254/wjh.v12.i11.1076. PMID: 33312431; PMCID: PMC7701972. 6: Yu YF, Chen Y, Shen XF, Wang RJ, Shen JW, Fang ZH. [Entecavir improves the reproductive function of male patients with chronic hepatitis B]. Zhonghua Nan Ke Xue. 2020 Apr;26(4):326-330. Chinese. PMID: 33351299. 7: Inoue J, Akahane T, Kobayashi T, Obara N, Umetsu T, Kakazu E, Ninomiya M, Iwata T, Sano A, Tsuruoka M, Sato K, Masamune A. Switching to tenofovir disoproxil fumarate in entecavir-treated chronic hepatitis B patients: A pilot randomized controlled study. Biomed Rep. 2021 Feb;14(2):20. doi: 10.3892/br.2020.1396. Epub 2020 Dec 1. PMID: 33335726; PMCID: PMC7739848. 8: Wu CJ, Chau GY, Lee IC, Huo TI, Su CW, Hou MC, Huang YH. Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapy. J Formos Med Assoc. 2020 Dec 14:S0929-6646(20)30596-9. doi: 10.1016/j.jfma.2020.11.019. Epub ahead of print. PMID: 33334659. 9: Wani MA, Sodhi JS, Yatoo GN, Shah A, Geelani S, Zargar SA, Gulzar GM, Khan M, Aziz SA. Clinical Profile and Efficacy of Antivirals in Hepatitis B Virus Reactivation, in Patients With Cancer Receiving Chemotherapy. J Clin Exp Hepatol. 2020 Nov-Dec;10(6):590-598. doi: 10.1016/j.jceh.2020.06.008. Epub 2020 Jul 8. PMID: 33311896; PMCID: PMC7719970. 10: Chang JW, Kim SU. Authors' response: Additional more factors should be included in predicting risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Viral Hepat. 2020 Dec 11. doi: 10.1111/jvh.13450. Epub ahead of print. PMID: 33305419. 11: Chen CH, Chen CY, Wang JH, Lai HC, Hung CH, Lu SN, Peng CY. Comparison of incidence of hepatocellular carcinoma between chronic hepatitis B patients with cirrhosis treated with entecavir or tenofovir in Taiwan - a retrospective study. Am J Cancer Res. 2020 Nov 1;10(11):3882-3895. PMID: 33294274; PMCID: PMC7716174. 12: Gu X, Zhang Y, Zou Y, Li X, Guan M, Zhou Q, Qiu J. Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents. Bioorg Med Chem. 2020 Nov 28;29:115892. doi: 10.1016/j.bmc.2020.115892. Epub ahead of print. PMID: 33285406. 13: Reynolds G, Stewart T, Harrison SJ, Spencer A, Teh BW. Hepatitis B reverse seroconversion despite entecavir prophylaxis in a myeloma patient on multiple novel agents: a case report and review of the literature. Leuk Lymphoma. 2020 Dec 4:1-7. doi: 10.1080/10428194.2020.1855343. Epub ahead of print. PMID: 33275059. 14: Peng CW, Jeng WJ, Chien RN, Liaw YF. The impact of hepatitis flare on HBeAg loss was effective mainly in the first year of Nucleot(s)ide therapy in chronic hepatitis B. J Viral Hepat. 2020 Dec 3. doi: 10.1111/jvh.13449. Epub ahead of print. PMID: 33274536. 15: Mohamed K, Yazdanpanah N, Saghazadeh A, Rezaei N. Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review. Bioorg Chem. 2021 Jan;106:104490. doi: 10.1016/j.bioorg.2020.104490. Epub 2020 Nov 19. PMID: 33261845; PMCID: PMC7676368. 16: Kim HL, Kim GA, Park JA, Kang HR, Lee EK, Lim YS. Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B. Gut. 2020 Nov 25:gutjnl-2020-321309. doi: 10.1136/gutjnl-2020-321309. Epub ahead of print. PMID: 33239344. 17: Suzuki K, Suda G, Yamamoto Y, Furuya K, Baba M, Nakamura A, Miyoshi H, Kimura M, Maehara O, Yamada R, Kitagataya T, Yamamoto K, Shigesawa T, Nakamura A, Ohara M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Sakamoto N; NORTE Study Group. Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection. J Gastroenterol. 2020 Nov 19. doi: 10.1007/s00535-020-01750-3. Epub ahead of print. PMID: 33211179. 18: Luo M, Wu S, Kalkeri R, Ptak RG, Zhou T, Van Mellaert L, Wang C, Dumbre SG, Block T, Groaz E, De Jonghe S, Li Y, Herdewijn P. Scalable Synthesis, In Vitro cccDNA Reduction, and In Vivo Antihepatitis B Virus Activity of a Phosphonomethoxydeoxythreosyl Adenine Prodrug. J Med Chem. 2020 Nov 25;63(22):13851-13860. doi: 10.1021/acs.jmedchem.0c01381. Epub 2020 Nov 16. PMID: 33191744. 19: Mak LY, Cloherty G, Wong DK, Gersch J, Seto WK, Fung J, Yuen MF. HBV RNA profiles in chronic hepatitis B patients under different disease phases and anti-viral therapy. Hepatology. 2020 Nov 6. doi: 10.1002/hep.31616. Epub ahead of print. PMID: 33159329. 20: Huang HH, Hsiao FY, Chen HM, Wang CY, Ko BS. Antiviral prophylaxis for hepatitis B carriers improves the prognosis of diffuse large B-cell lymphoma in Taiwan - a population-based study. Br J Haematol. 2021 Jan;192(1):110-118. doi: 10.1111/bjh.17142. Epub 2020 Oct 31. PMID: 33131074.